In the second big M&A deal of the year following BMS’s acquisition of Celgene, Eli Lilly has announced it will acquire precision cancer medicine specialists Loxo Oncology in a deal worth $8 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results